Health ❯Healthcare ❯Oncology

Blood Cancers

Multiple Myeloma Leukemia Myeloma Treatments T Cell Acute Lymphoblastic Leukemia Blastic Plasmacytoid Dendritic Cell Neoplasm

Pivekimab Sunirine Shows 85% Response Rate in BPDCN Trial

Frontline patients in the CADENZA trial saw a median overall survival of 16.6 months with peripheral edema as the primary manageable side effect.

Next-Generation CAR-T Therapies Deliver Remission in T-Cell Cancers and Extend Survival in Gastric and Brain Tumors

Frequent Blood Donation Linked to Beneficial Genetic Changes in Blood Stem Cells